PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.00%
Positive revenue growth while 3391.T is negative. John Neff might see a notable competitive edge here.
3.45%
Positive gross profit growth while 3391.T is negative. John Neff would see a clear operational edge over the competitor.
-12.72%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-11.49%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
44.66%
Positive net income growth while 3391.T is negative. John Neff might see a big relative performance advantage.
44.66%
Positive EPS growth while 3391.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
44.66%
Positive diluted EPS growth while 3391.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.07%
10Y revenue/share CAGR under 50% of 3391.T's 119.50%. Michael Burry would suspect a lasting competitive disadvantage.
-13.38%
Negative 5Y CAGR while 3391.T stands at 77.78%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
32.50%
3Y revenue/share CAGR 1.25-1.5x 3391.T's 26.23%. Bruce Berkowitz might see better product or regional expansions than the competitor.
-100.00%
Negative 10Y OCF/share CAGR while 3391.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
141.27%
Below 50% of 3391.T's 321.49%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
37.60%
5Y net income/share CAGR at 50-75% of 3391.T's 72.43%. Martin Whitman might see a shortfall in operational efficiency or brand power.
124.28%
3Y net income/share CAGR above 1.5x 3391.T's 34.42%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
132.72%
10Y equity/share CAGR at 75-90% of 3391.T's 152.48%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
27.89%
Below 50% of 3391.T's 90.67%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
71.06%
3Y equity/share CAGR above 1.5x 3391.T's 46.34%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-25.00%
Cut dividends over 10 years while 3391.T stands at 91868.84%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
2.27%
Below 50% of 3391.T's 175.20%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
-25.00%
Negative near-term dividend growth while 3391.T invests at 126.32%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-37.14%
Firm’s AR is declining while 3391.T shows 2.90%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
3.40%
Inventory growth well above 3391.T's 0.59%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
8.47%
Asset growth above 1.5x 3391.T's 5.05%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.41%
BV/share growth above 1.5x 3391.T's 4.18%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
25.46%
We have some new debt while 3391.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-42.69%
We cut SG&A while 3391.T invests at 3.53%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.